Ronnie Yeager
Research Fellow, Emerging Therapeutic Platforms Abbvie
Research Fellow/Board Certified Toxicologist with over 15 years of drug development experience with small and large molecule programs across multiple therapeutic areas. Experienced in development and execution of non-clinical safety strategies, with focus on antibody drug conjugates (ADCs) and immuno-oncology programs across various formats/modalities. Have led and contributed to platform-related safety assessments and toxicity model development within oncology discovery. Supported compound advancement to FIH trials and regulatory filings/interactions (US and ex-US), including breakthrough therapy/accelerated approval pathways, through mid-late stage clinical development. Preclinical Safety lead for Emrelis™ (telisotuzumab-vedotin); AbbVie’s first FDA approval of an internally developed ADC solid tumor asset (lung cancer). Strong record of leading and collaborating within a matrixed organization both cross-functionally and cross-site (US and Europe).
Seminars
- Recapitulating clinically relevant ADC toxicity in an acute rodent IV infusion model to increase efficiency and reduce costs within payload discovery screening
- Utilising infusion models to better understand potential species-specific sensitivities to ADC toxicities
- Giving merit for infusion models to inform anticipated ADC payload PK exposures, respective of SOC or comparator drugs, to aid risk benefit analysis for ADC approaches
